Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 30, 2017Digestive Diseases and SciencesOpen Access

Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLisa SmitsPharmo InstituteAGAnna GrelackLDLauranne DerikxErasmus MC

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Smits et al. (2017) studied this question.

synapsesocial.com/papers/6a830b41332c0e417ef46608https://doi.org/10.1007/s10620-017-4661-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia2015 · 73 citations
  2. 2Changes in Biosimilar Knowledge among European Crohn’s Colitis Organization [ECCO] Members: An Updated Survey2016 · 98 citations
  3. 3Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis2006 · 472 citations
  4. 4Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study2016 · 88 citations